ERBB2 and breast cancer: A targeted cardioncological approach, in patients with evidence of cardiotoxicity during HER-2 inhibitor therapy, can favorably influence the oncological management of breast cancer patients, enabling the completion of active treatment regimens and reducing the adverse impact of chemotherapy on left ventricular function, with a reduced effect on HF events, and a higher rate of survival.